ReviewFrontiers in immunology2019
Immunopathogenesis of Juvenile Systemic Sclerosis.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Distinct by Design: Unraveling the Unique Clinical and Transcriptomic Identity of Juvenile Scleromyositis Overlap Compared to Juvenile Systemic Sclerosis and Juvenile Dermatomyositis: Implications for Care and Pathogenesis.ACR open rheumatology · 2026Article
- Incidence and prevalence of juvenile SSc in the United States: An analysis by age group.Journal of scleroderma and related disorders · 2025Article
- A causal relationship between type 1 diabetes and risk of systemic sclerosis: a bidirectional two-sample Mendelian randomization study.Diabetology & metabolic syndrome · 2025Article
- An updated overview of Juvenile systemic sclerosis in a French cohort.Pediatric rheumatology online journal · 2025Article
- Spatial Transcriptomics Identifies Cellular and Molecular Characteristics of Scleroderma Skin Lesions: Pilot Study in Juvenile Scleroderma.International journal of molecular sciences · 2024Article
- Orofacial Complications of the Connective Tissue Disease Systemic Sclerosis.Journal of dental research · 2024Review
- Clinical characteristics of juvenile systemic sclerosis in Korea: 31-year single-center study.Journal of rheumatic diseases · 2024Article
- Cardiovascular risk and inflammation in a population with autoimmune diseases: a narrative review.Frontiers in immunology · 2024Review
- Can vitamin D be an adjuvant therapy for juvenile rheumatic diseases?Rheumatology international · 2023Review
- Application and performance of disease activity indices proposed for patients with systemic sclerosis in an international cohort of patients with juvenile systemic sclerosis.Journal of scleroderma and related disorders · 2023Article
- Juvenile diabetes and systemic sclerosis: just a coincidence?Pediatric rheumatology online journal · 2022Article
- Systemic sclerosis-associated pulmonary arterial hypertension in children.Cardiovascular diagnosis and therapy · 2021Review
- DNA methylation patterns in juvenile systemic sclerosis and localized scleroderma.Clinical immunology (Orlando, Fla.) · 2021Article
- Early detection of ventricular dysfunction in juvenile systemic sclerosis by speckle tracking echocardiography.Rheumatology (Oxford, England) · 2021Article
- Juvenile systemic sclerosis - observations of one clinical centre.Reumatologia · 2021Article
- The Role of Cutaneous Type I IFNs in Autoimmune and Autoinflammatory Diseases.Journal of immunology (Baltimore, Md. : 1950) · 2020Review
- Treatment in Juvenile Scleroderma.Current rheumatology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
Abstract
Juvenile-onset systemic sclerosis (jSSc) is a rare and severe autoimmune disease with associated life-threatening organ inflammation and evidence of fibrosis. The organ manifestations of jSSc resemble adult SSc, but with better outcomes and survival. The etiology of jSSc appears to reflect adult-onset SSc, with similar inflammatory mediators and autoantibodies, but with a significant population of children with uncharacterized anti-nuclear antibodies. The genetics of patients with jSSc differ from women with SSc, resembling instead the genes of adult males with SSc, with additional HLA genes uniquely associated with childhood-onset disease. Current treatments are aimed at inhibiting the inflammatory aspect of disease, but important mechanisms of fibrosis regulated by dermal white adipose tissue dendritic cells may provide an avenue for targeting and potentially reversing the fibrotic stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.